VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Cov19VaxKB
Host Responses
VaximmutorDB
VIGET
Vaxafe
Vaxar
Vaxism
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign2
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UM Logo

Vaccine Detail

Allogeneic Cellular Vaccine 1650-G
Vaccine Information
  • Vaccine Name: Allogeneic Cellular Vaccine 1650-G
  • Target Pathogen: Cancer
  • Target Disease: Cancer
  • Vaccine Ontology ID: VO_0007219
  • Type: Other
  • Status: Clinical trial
  • Host Species for Licensed Use: Human
  • Host Species as Laboratory Animal Model: Human
  • Antigen: ERBB2
  • CEACAM5 (CEA) gene engineering:
    • Type: Recombinant protein preparation
    • Description:
    • Detailed Gene Information: Click Here.
  • WT1 gene engineering:
    • Type: Recombinant protein preparation
    • Description:
    • Detailed Gene Information: Click Here.
  • MAGEA2 gene engineering:
    • Type: Recombinant protein preparation
    • Description:
    • Detailed Gene Information: Click Here.
  • Adjuvant:
  • Preparation: 1650-G comprises an apoptosed and lethally irradiated tumor cell allogeneic line and GMCSF (Berlex Inc., Richmond, CA). The lung tumor cell line 1650 is known to overexpress Her-2/neu, carcinoembryonic antigen, Mage 2, WT-1, survivin, and New York esophageal squamous cell carcinoma 1 antigen (Hirschowitz et al., 2011).
    The vaccine (delivered intradermally) is composed of four class II restricted HER-2/neu peptides plus 125 μg GM-CSF (Hirschowitz et al., 2006).
    DC vaccines were generated from CD14+ precursors, pulsed with apoptotic bodies of an allogeneic NSCLC cell line that overexpressed Her2/neu, CEA, WT1, Mage2, and survivin (Hirschowitz et al., 2004).
  • Description: A pluripotent, allogeneic, tumor cell vaccine composed of irradiated tumor cells from the non-small cell lung cancer (NSCLC) cell line 1650 and the immunoadjuvant recombinant granulocyte-macrophage colony stimulating factor (GM-CSF) (1650-G), with potential immunostimulating and antineoplastic activities. Upon administration, allogeneic cellular vaccine 1650-G may stimulate the immune system to exert a cytotoxic T-lymphocyte (CTL) immune response against tumor-associated antigens (TAAs) expressed on NSCLC cells. GM-CSF potentiates the antitumor immune response. The 1650 cell line is used as a source for TAAs. (NCIT_C119759).
Host Response
References
Hirschowitz et al., 2004: Hirschowitz EA, Foody T, Kryscio R, Dickson L, Sturgill J, Yannelli J. Autologous dendritic cell vaccines for non-small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2004; 22(14); 2808-2815. [PubMed: 15254048].
Hirschowitz et al., 2006: Hirschowitz EA, Hiestand DM, Yannelli JR. Vaccines for lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2006; 1(1); 93-104. [PubMed: 17409835].
Hirschowitz et al., 2011: Hirschowitz EA, Mullins A, Prajapati D, Baeker T, Kloecker G, Foody T, Damron K, Love C, Yannelli JR. Pilot study of 1650-G: a simplified cellular vaccine for lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2011; 6(1); 169-173. [PubMed: 21150468].
NCIT_C119759: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C119759]